 The study will be a prospective, randomized, double blind placebo-controlled trial. The study population will include males and females, ages 18-65, who fulfill criteria for primary DSM-5 OCD as determined by a structured interview. At screening, patients must have a YBOCS score 20 and a MADRS score 18. 